Latest Earnings Results: Q2 '26
Estimated EPS
-$1.65
Reported EPS
-$1.69
Surprise
-2.13%
Estimated Rev
$26.4M
Reported Rev
$44.74M
Surprise
+69.52%
• Reported GAAP EPS of -$1.69 up 12.44% YoY • Reported revenue of $44.74M up 259.25% YoY
Bullish Takeaway
Agios Pharmaceuticals achieved significant revenue growth for mitapivat, secured European marketing authorization for thalassemia treatment, and expanded the company pipeline through the strategic licensing of a high-potential SYK inhibitor program.
Bearish Takeaway
Agios Pharmaceuticals continues to record net losses and increased research expenses, while the company also discontinued development of tebapivat in two key indications due to insufficient clinical trial performance results.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$1.65 | -$1.69 | -2.13% | MISSED |
Q1 '26 | -$1.80 | -$1.69 | 6.29% | BEAT |
Q4 '25 | -$1.95 | -$1.86 | 4.80% | BEAT |
Q3 '25 | -$1.90 | -$1.78 | 6.14% | BEAT |
Q2 '25 | -$1.81 | -$1.93 | -6.78% | MISSED |
